CST2

Across TCGA pan-cancer cohorts, CST2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CST2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CST2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CST2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, KIRP, and SARC are the cancer types where CST2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	III,IV	0.111	0.814	<.001	12	view →
KIRP	DFS	Median	All	0.133	0.605	.014	6	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →
BRCA	DFS	Median	All	0.153	0.526	.037	4	view →
UCEC	OS	Median	II,III,IV	1.000	0.466	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CST2–SKCM (OS)

Open the SKCM breakdown →